Business
Cardio Diagnostics Holdings, Inc to Attend 22nd Annual AHOU Conference
CHICAGO--(BUSINESS WIRE)-- Cardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is participating and exhibiting at the 22nd Annual
About this update from Cardio Diagnostics Holdings Inc.
[{"type":"text","content":" CHICAGO--(BUSINESS WIRE)--\nCardio Diagnostics Holdings, Inc (NASDAQ: CDIO) today announced that it is participating and exhibiting at the 22nd Annual Association of Home Office Underwriters (AHOU) Conference, a premier event for the life insurance underwriting industry. The conference will take place from April 16-19, 2023, at The Diplomat Beach Resort in Hollywood, Florida. Cardio Diagnostics will be exhibiting at Booth 108.\n\n\nThis year’s AHOU conference, themed “Waves of Change: Navigating the Underwriting Evolution Together,” will bring together industry leaders to discuss the latest trends and innovations in life insurance underwriting, including ways to address the impact of heart disease - the most common cause of deaths resulting in life insurance payouts\n\n\nCardio Diagnostics is at the forefront of precision cardiovascular medicine, combining epigenetics and artificial intelligence to revolutionize the early detection, prevention and treatment of cardiovascular disease, the leading cause of death in the United States. The Company has already introduced two solutions, Epi+Gen CHD and PrecisionCHD, focused on assessing the risk for and detecting coronary heart disease (CHD), the most common type of cardiovascular disease and the primary cause of heart attacks.\n\n\nIn addition, Cardio Diagnostics will showcase its Actionable Clinical Intelligence™ platform, which provides critical insights by connecting the biomarkers measured by the tests to CHD.\n\n\n“We’re thrilled to be attending the AHOU’s annual conference,” said Meesha Dogan, Ph.D., CEO of the Company. “In the dynamic and evolving landscape of the life insurance industry, forward-thinking insurers are increasingly recognizing the strategic value of integrating advanced technology into their underwriting processes and health management initiatives. At the forefront of this transformation is the deployment of cutting-edge technological solutions that offer unparalleled capabilities in detecting and assessing the risk of heart disease—an ailment that has long been identified as the primary driver of life insurance claim payouts.”\n\n\nCardio Diagnostics’ suite of innovative molecular heart disease solutions is designed to address this challenge head-on by facilitating early diagnosis of heart disease, thereby unlocking significant value for insurers and their po...